Literature DB >> 9808202

Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis.

E Wallström1, M Khademi, M Andersson, R Weissert, C Linington, T Olsson.   

Abstract

Multiple sclerosis (MS) is a central nervous system-specific inflammatory and demyelinating disease where a myelin-directed autoimmune response is thought to be pathogenetically relevant. Myelin oligodendrocyte glycoprotein (MOG) is a surface-exposed minor myelin component that is a prime candidate autoantigen. We have investigated peripheral blood lymphocyte responses to synthetic 15-26 amino acids long overlapping MOG peptides in 20 MS patients and 14 healthy controls with the MS-associated HLA haplotype DR2(15). There were significantly increased responses, in terms of numbers of cells secreting IFN-gamma detected by Elispot in response to several MOG-derived peptides in the MS patients, but not the healthy controls. MOG peptide 63-87 evoked the strongest response, and the stimulatory property of this peptide was confirmed in additional DR2(15)+ MS patients where a peptide concentration-dependent proliferative response, which was inhibited by the addition of anti-HLA class II antibodies, was observed. This is the first work detailing putative immunodominant T cell epitopes of MOG in DR2(15)+ MS patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9808202     DOI: 10.1002/(SICI)1521-4141(199810)28:10<3329::AID-IMMU3329>3.0.CO;2-B

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  26 in total

Review 1.  T cells, cytokines, and autoantigens in multiple sclerosis.

Authors:  B Gran; A Rostami
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

2.  Skewed autoantibody reactivity to the extracellular domain of myelin oligodendrocyte glycoprotein in multiple sclerosis.

Authors:  Maria V Tejada-Simon; Jian Hong; Victor M Rivera; Jingwu Z Zhang
Journal:  Immunology       Date:  2002-12       Impact factor: 7.397

Review 3.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

4.  Eae19, a new locus on rat chromosome 15 regulating experimental autoimmune encephalomyelitis.

Authors:  Jian Rong Sheng; Maja Jagodic; Ingrid Dahlman; Kristina Becanovic; Rita Nohra; Monica Marta; Ellen Iacobaeus; Tomas Olsson; Erik Wallström
Journal:  Genetics       Date:  2005-02-16       Impact factor: 4.562

5.  White matter disease: Roles of anti-MOG antibodies in demyelinating diseases.

Authors:  Tomas Olsson
Journal:  Nat Rev Neurol       Date:  2011-04-12       Impact factor: 42.937

6.  Increased frequencies of myelin oligodendrocyte glycoprotein/MHC class II-binding CD4 cells in patients with multiple sclerosis.

Authors:  Khadir Raddassi; Sally C Kent; Junbao Yang; Kasia Bourcier; Elizabeth M Bradshaw; Vicki Seyfert-Margolis; Gerald T Nepom; William W Kwok; David A Hafler
Journal:  J Immunol       Date:  2011-06-08       Impact factor: 5.422

7.  Multiparameter Flow Cytometric Assays to Quantify Effector and Regulatory T-Cell Function in Multiple Sclerosis.

Authors:  Sushmita Sinha; Michael P Crawford; Sterling B Ortega; Nitin J Karandikar
Journal:  J Mult Scler (Foster City)       Date:  2015-01

Review 8.  Insights into the immunopathogenesis of multiple sclerosis.

Authors:  Niels Hellings; Jef Raus; Piet Stinissen
Journal:  Immunol Res       Date:  2002       Impact factor: 2.829

Review 9.  Transgenic mouse models of multiple sclerosis.

Authors:  Tanja Scheikl; Béatrice Pignolet; Lennart T Mars; Roland S Liblau
Journal:  Cell Mol Life Sci       Date:  2010-08-17       Impact factor: 9.261

10.  Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis.

Authors:  Jan D Lünemann; Sandra Rückert; Florian Kern; Uwe Wendling; Ruud van der Zee; Hans D Volk; Frauke Zipp
Journal:  J Neurol       Date:  2004-09       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.